Switching HIV medication after viral failure
Part of Immune system & allergy, Infections clinical trials.
This study tests whether switching to a different HIV pill (BIC/FTC/TAF) is safe and effective for people who had a viral failure while on the long-acting injectable CAB/RPV. It may offer a new option for those who need to change treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and are over 18 years old.
- You had a confirmed viral failure (virus became detectable) while on the injectable CAB/RPV in the last three years.
- You do not have resistance to the medications FTC and TAF (which are part of the new pill).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests restarting a once-daily HIV pill (containing bictegravir, emtricitabine, and tenofovir alafenamide) on the same day it is prescribed, after stopping a different type of HIV medicine. It aims to see if this safe and convenient approach works well for people like you.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.